vusolimogene oderparepvec

AXP000010.2 · Oncolytic virus

Platform
HSV-1 (RH018A strain)
Originator
Replimune
Sponsor
Replimune

Names

NameTypeSource
vusolimogene oderparepvecpreferred name, INNcurator, ncit
Tudriqevbrandfda
RP1 ambiguouscodencit
vusolimogene oderparepvec-wtpgsynonymfda

Virus

Role
Oncolytic
Family
Orthoherpesviridae
Virus
herpes simplex virus 1 (NCBI Taxonomy 10298)
Strain
RH018A
Replication
conditionally replicating
Modifications
RL1 (ICP34.5) and US12 (ICP47) deleted
Transgenes
CSF2, GALV-GP R-
Route
intratumoral
Source
evidence

Cross-references

NCI Thesaurus
C158074
Wikidata
Q141304044
FDA UNII
45KLN7N6UV

Approvals

AgencyRegionDateStatusBrandIndicationSource
FDAUS2026-08-06conditionalTudriqevAdvanced melanoma, with nivolumab (accelerated approval)source

Clinical trials (8)

TrialTitleStatusPhaseStartPrimary completionEnrolmentConditions
NCT07862530Neoadjuvant RP2 + Nivolumab in Patients With MelanomaNot yet recruitingPhase 22026-12-312028-02-2734MelanomaCutaneous Melanoma Resectable, Melanoma
NCT06898970Intratumoral Vusolimogene Oderparepvec (VO) in Combination With Pembrolizumab for AngiosarcomaRecruitingPhase 22026-01-092029-10-3118Angiosarcoma; Angiosarcoma, Adult
NCT06264180VO and Nivolumab vs Physician's Choice in Advanced Melanoma That Progressed on Anti-PD-1 & Anti-CTLA-4 Drugs [IGNYTE-3]RecruitingPhase 32024-07-112030-09-30400Advanced Melanoma
NCT06067061"neoBREASTIM": Atezolizumab Plus RP1 Oncolytic Immunotherapy in the NeoAdjuvant Setting of Triple-Negative Breast CancerTerminatedPhase 1/22024-04-052025-05-072Triple Negative Breast Neoplasms
NCT06216938RP1 in Primary Melanoma to Reduce the Risk of Sentinel Lymph Node MetastasisRecruitingEarly phase 12024-03-072028-03-3125Melanoma
NCT04050436Study Evaluating Cemiplimab Alone and Combined With RP1 in Treating Advanced Squamous Skin CancerActive not recruitingPhase 22019-10-082025-09231Advanced Cutaneous Squamous Cell Carcinoma; Cutaneous Squamous Cell Carcinoma; Metastatic Cutaneous Squamous Cell Carcinoma
NCT03767348Study of RP1 Monotherapy and RP1 in Combination With Nivolumab (IGNYTE)Active not recruitingPhase 22017-09-202028-06340Cutaneous Melanoma; Microsatellite Instability-High (MSI-H); Non-Small Cell Lung Cancer (NSCLC); Non-melanoma Skin Cancer (NMSC)
NCT06590480An Expanded Access Program for VO (RP1) in Combination With Nivolumab in Patients With Advanced MelanomaNo longer availableAdvanced Melanoma
Unconfirmed matches (1)

Trials that mention one of the names in a weaker way (a code only in the title, a short or ambiguous name). Not counted above.

TrialTitleStatusPhaseStartPrimary completionEnrolmentConditionsMatched by
NCT05858229Neo-adjuvant Treatment for Squamous Cell Carcinoma Using Direct Tumor Injection With RP1.Active not recruitingPhase 1/22023-06-162025-1212RP1; Squamous Cell Carcinomaintervention named: RP1

Recent changes

No changes recorded in its trials yet.

Clinical papers

PubMedTitleJournalYearLinked by
PMID 40627813RP1 Combined With Nivolumab in Advanced Anti-PD-1-Failed Melanoma (IGNYTE).Journal of clinical oncology : official journal of the American Society of Clinical Oncology2025cited by trial NCT03767348
PMID 31399043Development of a new fusion-enhanced oncolytic immunotherapy platform based on herpes simplex virus type 1.Journal for immunotherapy of cancer2019cited by trial NCT03767348

Other papers

Preclinical studies, reviews and other papers that name it.

PubMedTitleJournalYearLinked by
PMID 41775431Effects of oncolytic immunotherapy with RP1 (vusolimogene oderparepvec) on immune cells mediate responsiveness to anti-PD-1 via STING-mediated interferon signaling.Journal for immunotherapy of cancer2026name in title: vusolimogene oderparepvec
PMID 42346244The Evolving Role of Intralesional Therapy in In-Transit Melanoma.Current oncology (Toronto, Ont.)2026name in abstract: vusolimogene oderparepvec
PMID 42582160Biodistribution, shedding, and transmissibility of vusolimogene oderparepvec (RP1).Frontiers in oncology2026name in title: vusolimogene oderparepvec
PMID 42832393Vusolimogene oderparepvec (Tudriqev) - an oncolytic viral therapy for melanoma.The Medical letter on drugs and therapeutics2026name in title: vusolimogene oderparepvec
PMID 42925389Vusolimogene Oderparepvec: First Approval.Drugs2026name in title: vusolimogene oderparepvec
PMID 42988789Vusolimogene oderparepvec-wtpg (Tudriqev): a new engineered viral immunotherapy for intratumoral use.Immunopharmacology and immunotoxicology2026name in title: vusolimogene oderparepvec-wtpg
PMID 40733704Advances in Oncolytic Viral Therapy in Melanoma: A Comprehensive Review.Vaccines2025name in abstract: vusolimogene oderparepvec
PMID 41148835The Evolution, Current Landscape, and Future Prospects of Oncolytic Virotherapy in Melanoma: Talimogene Laherparepvec and Beyond.Cells2025name in abstract: vusolimogene oderparepvec

Notes

FDA accelerated approval 6 Aug 2026 as Tudriqev (vusolimogene oderparepvec-wtpg), with nivolumab, in advanced melanoma. Second transgene is a gibbon ape leukaemia virus envelope glycoprotein (GALV-GP R-), which is viral, so not in targets. Transgenes moved from targets to virus.tsv (spec 0.2).

How to cite

vusolimogene oderparepvec (AXP000010.2). The Abstractinator program registry, release 2026-11-17+2c46e992acfc. https://abstractinator.me/registry/AXP000010.html

Something wrong or missing? Suggest a correction (a GitHub issue; please link your evidence). Entry created 2026-11-11, updated 2026-11-11.